4Dx Preclinical Scanner Project to Rapidly Manufacture 2 Preclinical Scanner Units for Delivery in Major US Hospitals
Melbourne, Australia, 19 April 2017: 4Dx Group “4Dx”, Hydrix Pty Ltd “Hydrix”, and Monash University are collaborating “4Dx Pre-Clinical Scanner Project consortium” to rapidly manufacture two pre-clinical scanners for delivery to two major American medical research hospitals by the end of the year. A further three units will be supplied to other world leading hospitals […]
4Dx visits London, participates in House of Lords event
4Dx is pleased to inform you that our Chairman and CEO, Andreas Fouras, will be lead speaker at a lunchtime debate at the All Party Parliamentary Engineering Group ‘APPEG’ in the House of Lords, London on Tuesday 21st March. The debate series represents a plank of the APPEG program to enable contact and involvement between parliamentarians and […]
4Dx TO PUBLICLY ANNOUNCE PRELIMINARY CLINICAL TRIAL DATA AT PRESTIGIOUS WORLD LUNG IMAGING EVENT
Melbourne, Australia, 20 February, 2017: Dr. Andreas Fouras, founder and CEO of medical technology company 4Dx Limited, will present preliminary clinical data at the prestigious World Lung Imaging Workshop on the 2nd of March at the University of Pennsylvania. The software technology developed by 4Dx provides richer information, allowing for earlier detection of respiratory related […]
NEW STAFF APPOINTMENT: KAREN SIU, PhD- Programme Manager- Medical Device Development
Dr Karen Siu obtained her PhD from Monash University in 2003 in X-ray Physics. Her postdoctoral work as an Australian Synchrotron Research Program Fellow allowed her to explore the applications of synchrotrons, or highly intense x-ray sources, to biomedical research studying cancers of the brain and breast. She focussed on synchrotron imaging for understanding the […]
4Dx To Close Series A Capital Raise
Melbourne, Australia, November 23, 2016: 4Dx Limited is pleased to announce that, due to an overwhelming response, as of 5pm, Friday, 9th December, 2016, the company’s $4m Series A capital round will be officially closed. It is anticipated that the round will close oversubscribed. 4Dx founder and Chairman, Andreas Fouras, said, “4Dx is extremely pleased […]
A BREATH OF FRESH AIR FOR MEDICAL IMAGE TECHNOLOGY
4Dx was featured in an article in Australias national daily newspaper, The Australian today. Andreas Fouras, Founder and CEO of 4Dx is interviewed and the article discusses the new software for imaging lung function devised by 4Dx. A BREATH OF FRESH AIR FOR MEDICAL IMAGE TECHNOLOGY A “dream job” studying airflow through jet engines has […]
Appointment of General Manager – Notting Hill Devices
4Dx is excited to announce that Paul Cooke will be taking on the role of General Manager of 4Dx’s specialist hardware subsidiary, Notting Hill Devices. As Paul moves into this role, he will be stepping aside from his role as Non-Executive Director, effective 1st September. During his tenure as Non-Executive Director, Paul played a key […]
Monash license agreement changes
A number of positive changes have been made to the key licence agreement with Monash University (which grants 4Dx rights to commercialise this technology in exchange for royalty payments). Most notable among these changes is that the funding threshold for assignment of patents has been lowered to A$6.5 million from A$10 million. Once this lower […]
Andreas Fouras, CEO of 4Dx, says backing bright people is a bright idea
Andreas Fouras, Founder and CEO of 4Dx, spoke with Nature Index on the recent call from the National Health and Medical Research Council (NHMRC) for public consultation on the structural review of their grant program. Following criticism that current funding models are failing to support researchers across all stages of their careers, the NHMRC have opened the debate around three proposed alternative models to […]
4Dx retail round closes with full subscription
We are pleased to announce that our recent retail offer of shares is now fully subscribed after successfully raising AU$500,000. It is very encouraging to gain backing so enthusiastically from retail investors committed to seeing our technology come to market as fast as possible. These funds take us a step closer to commercialising our technology through ongoing clinical […]
